The Blueprint

The 5 Levels of FDA
Cybersecurity Readiness

Five levels. One model. Use it to benchmark your team and eliminate premarket documentation risks before filing.

Start free assessment →
1
Coming from: Baseline / Ad-hoc entry
Moving toward: Level 2 — Documented

Level 1: Reactive

Cybersecurity treated as an operational afterthought.

Security measures are completely detached from product architecture. Device design progresses until compliance friction forces an emergency check. Technical documentation is non-existent or purely nominal until an official FDA demand arrives.

Typically Present

  • Basic off-the-shelf OS security assumptions
  • Standard commercial developer methodologies
  • Informal engineering logs or notes

Missing Architecture

  • No dedicated SPDF lifecycle framework
  • No documented threat modeling assets
  • No production-ready SBOM artifacts
Regulatory Outcome Status High probability of a direct Refuse to Accept (RTA) decision or an extended 12+ month deficiency cycles during formal review.
Transition to Level 2:
  1. Formally isolate cybersecurity criteria into a separate engineering review checklist.
  2. Extract initial software composition inventories to build a static snapshot.
  3. Run an introductory vulnerability sweep on top-level runtime environments.
2
Coming from: Level 1 — Reactive
Moving toward: Level 3 — Integrated

Level 2: Documented

Basic compliance artifacts exist, but stay isolated in siloed silos.

Technical assets (like basic threat maps or static spreadsheets) are maintained internally but remain completely disconnected from the actual design controls process. Deliverables are checked off manually but lack system traceability features.

Typically Present

  • Manual or spreadsheet-based SBOM tracks
  • Drafted static threat matrices
  • Basic software update procedures outlined

Missing Architecture

  • Lack of cross-referenced component CVE traces
  • No full 524B gap validation matrix mappings
  • Threat model lacks end-to-end verification data
Regulatory Outcome Status Successfully bypasses basic RTA filters, but triggers significant Additional Information (AI) requests, delaying clinical commercial timelines.
Transition to Level 3:
  1. Convert static spreadsheets into standard machine-readable formats (CycloneDX JSON).
  2. Map every discovered system threat directly to design mitigation assets.
  3. Formalize a dedicated Vulnerability Management and Cybersecurity Plan.
3
Coming from: Level 2 — Documented
Moving toward: Level 4 — Proactive

Level 3: Integrated (The Compliance Baseline)

Cybersecurity formally engineered into 21 CFR 820.30 design controls.

Your Secure Product Development Framework (SPDF) is completely operational. Security controls are treated exactly like regular clinical indicators: designed with precision, tested dynamically, and structured to withstand institutional scrutiny.

Typically Present

  • CycloneDX / SPDX files cross-referenced with CVE databases
  • Dynamic threat modeling maps tied to active validation
  • Documented VMMP and live Coordinated Vulnerability Disclosure (CVD)

Missing Architecture

  • Automated post-market live alerting systems
  • Continuous deployment runtime testing sequences
  • Cross-functional institutional security governance
Regulatory Outcome Status High predictability for clean first-cycle FDA reviews with zero major cybersecurity deficiencies or structural documentation setbacks.
Transition to Level 4:
  1. Implement active vulnerability tracking software on internal deployment lines.
  2. Establish formal institutional SLAs to evaluate and patch runtime CVE alerts.
  3. Incorporate pre-submission guidance cycles with FDA reviewers for complex systems.
4
Coming from: Level 3 — Integrated
Moving toward: Level 5 — Continuous

Level 4: Proactive

Continuous postmarket monitoring paired with rapid response pipelines.

Compliance transitions from a premarket submission hurdle into an ongoing postmarket shield. The organization detects, patches, and publishes hotfixes long before third-party research networks identify downstream vectors.

Typically Present

  • Continuous automated dependency security scanners
  • Rigid internal critical patch deployment SLAs
  • Active vulnerability intake and testing operations

Missing Architecture

  • Automated regression tests during live compilation
  • Unified compliance indicators mapped to performance metrics
  • Fully integrated continuous AI/ML governance tracking
Regulatory Outcome Status Maintains pristine institutional compliance histories. Highly protected from unexpected field recalls or postmarket device safety alerts.
Transition to Level 5:
  1. Automate SBOM updates and compliance validations directly inside CI/CD lines.
  2. Establish ongoing metrics loops connecting security health to business KPIs.
  3. Formulate proactive testing playbooks for dynamic AI/ML models (PCCP tracks).
5
Coming from: Level 4 — Proactive
Moving toward: Total Operational Excellence

Level 5: Continuous

Compliance engineered directly into runtime code delivery systems.

Cybersecurity functions seamlessly as a competitive value asset rather than an administrative drag. Software changes automatically validate security indicators during active deployment. Regulatory frameworks expand naturally alongside scale expansion.

Typically Present

  • Automated compliance sign-offs integrated into code commits
  • Full alignment with active NIST CSF and ISO 27001 tracks
  • Predictive security operations built into systemic enterprise goals

Missing Architecture

  • None. Product development matches top military and critical asset standards.
Regulatory Outcome Status Unlocks total commercial freedom. Security infrastructure operates as an institutional trust magnet during major hospital enterprise sales cycles.

Where does your team sit?

Take the free 5-minute diagnostic assessment to benchmark your current level against official FDA Section 524B submission expectations.

Find Your Readiness Level